[12 December 2011]
Products Affected - Description
Myochrysine Injection, Akorn
50 mg/mL, 1 mL vial, package of 6 (NDC 17478-0533-01) - temporarily discontinued
50 mg/mL, 10 mL vial (NDC 17478-0533-10) - discontinued
Reason for the Shortage
- Akorn has Myochrysine injection on shortage due to raw material issues.
- There are no other manufacturers of gold sodium thiomalate.
Available Products
No presentations are available.
Estimated Resupply Dates
Akorn has discontinued Myochrysine injection and does not expect to return the product to market.
Updated
December 12, 2011; October 31, 2011; September 13, 2011; August 2, 2011; June 7, 2011; April 25, 2011; March 29, 2011; February 14, 2011; January 25, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins